Search Results - Haijuan Yu

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Cladding Light Stripper of High Average Stripped Power Density With High Attenuation of 39 dB and Low Temperature Rise

    Cladding Light Stripper of High Average Stripped Power Density With High Attenuation of 39 dB and Low Temperature Rise by Shuzhen Zou, Han Chen, Jingyuan Zhang, Haijuan Yu, Zhiyan Zhang, Jing Sun, Xuechun Lin

    Published 2018-01-01

    We demonstrate a 150-mm long cladding light stripper for kW-level operation with high attenuation and low temperature rising. The first 100 mm of the device was designed based on theoretical simulation to achieve uniform extraction of the high-power scattered cladding light and it was constructed by...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Tumor Invasion Distance Based on MRI Is a Novel Prognostic Indicator for I-IIIB Cervical Cancer Patients Treated with Radiotherapy

    Tumor Invasion Distance Based on MRI Is a Novel Prognostic Indicator for I-IIIB Cervical Cancer Patients Treated with Radiotherapy by Linying Liu, Jie Lin, Anyang Li, Ning Xie, Jianfeng Zheng, Youping Xiao, Xuefen Lin, Shizhong Wu, Haijuan Yu, Yang Sun

    Published 2025-06-01

    <b>Aims:</b>This study aimed to identify the prognostic value of tumor invasion distance (TID) based on MRI findings in cervical-cancer (CC) patients treated with radiotherapy (RT). <b>Methods</b>: A total of 218 CC patients diagnosed at Fujian Cancer Hospital from December 2...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study

    Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study by Jian Chen, Haijuan Yu, Yingtao Lin, Dan Hu, Li Liu, Renliang Fan, Jianping Zou, Lele Zang, Yao Lin, Rong Lin, Dezhao Chen, Xiaoying Weng, Fenfang Shen, Shaoyu Wang, Wei Zeng, Qihua Tian, Yun Yi, Yuanfeng Chen, Jinjin Miao, Bo Zhang, Yinxia Zou, Fengming Gao, Fengming Gao, Rong Lian, Lin Yang, Yang Sun

    Published 2025-07-01

    BackgroundImmunotherapy has become a powerful clinical strategy for treating recurrent or metastatic cervical cancer (R/M CC). Cadonilimab, a novel anti-PD-1/CTLA-4 bispecific antibody, has shown substantial clinical benefits in cancer treatment. However, there is no real-world evidence of cadonilim...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: